Matrix metalloproteinase inhibitors
Tóm tắt
The matrix metalloproteinases (MMPs) are a family of at least fifteen secreted and membrane-bound zinc-endopeptidases. Collectively, these enzymes can degrade all of the components of the extracellular matrix, including fibrallar and non-fibrallar collagens, fibronectin, laminin and basement membrane glycoproteins. MMPs are thought to be essential for the diverse invasive processes of angiogenesis and tumor metastasis. Numerous studies have shown that there is a close association between expression of various members of the MMP family by tumors and their proliferative and invasive behavior and metastatic potential. In some of human cancers a positive correlation has also been demonstrated between the intensity of new blood vessel growth (angiogenesis) and the likelihood of developing metastases. Thus, control of MMP activity in these two different contexts has generated considerable interest as a possible therapeutic target. The tissue inhibitors of metalloproteinases (TIMPs) are naturally occurring proteins that specifically inhibit matrix metalloproteinases, thus maintaining balance between matrix destruction and formation. An imbalance between MMPs and the associated TIMPs may play a significant role in the invasive phenotype of malignant tumors. TIMP-1 has been shown to inhibit tumor-induced angiogenesis in experimental systems. These findings raised the possibility of using an agent that affects expression or activity of MMPs as an anti-cancer therapy. TIMPs are probably not suitable for pharmacologic applications due to their short half-life in vivo. Batimastat (BB-94) and marimastat (BB-2516) are synthetic, low-molecular weight MMP inhibitors. They have a collagen-mimicking hydroxamate structure, which facilitates chelation of the zinc ion in the active site of the MMPs. These compounds inhibit MMPs potently and specifically. Batimastat was the first synthetic MMP inhibitor studied in humans with advanced malignancies, but its usefulness has been limited by extremely poor water solubility, which required intraperitoneal administration of the drug as a detergent emulsion. Marimastat belongs to a second generation of MMP inhibitors. In contrast to batimastat, marimastat is orally available. Both of these agents are currently in Phase I/II trials in US, Europe and Canada. Some other new agents, currently in clinical trials, have been shown to inhibit MMP production. Bryostatins, naturally occurring macrocyclic lactones, have both in vitro and in vivo activity in numerous murine and human tumors. In culture, bryostatin-1 has been shown to induce differentiation and halt the growth of several malignant cell lines. While the exact mechanism responsible for anti-tumor activity is unclear, an initial event in the action of bryostatin-1 is activation of protein kinase C (PKC), followed by its down regulation. Bryostatin-1 does not directly affect the activity of MMPs, but it can inhibit the production of MMP-1, 3, 9, 10 and 11 by inhibiting PKC. TIMP-1 levels could also be modulated by bryostatin-1, as it is encoded by a PKC responsive gene.
Tài liệu tham khảo
Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler-Stevenson WG, Liotta LA: Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 269:21505–21511, 1994
Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: a review. Critical Rev Oral Biol Med 4:197–250, 1993
Stetler-Stevenson WG, Liotta LA, Kleiner DE, Jr: Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7:1434–1441, 1993
Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, Lopez-Otin C: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269:16766–16773, 1994
Belaaouaj A, Shipley JM, Kobayashi DK, Zimonjic DB, Popescu N, Silverman GA, Shapiro SD: Human macrophage metalloelastase. Genomic organization, chromosomal location, gene linkage, and tissue-specific expression. J Biol Chem 270:14568–14575, 1995
Basset P, Wolf C, Rouyer N, Bellocq JP, Rio MC, Chambon P: Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer 74:1045–1049, 1994
Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P: Membrane-type matrix and metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92:2730–2734, 1995
Takino T, Sato H, Shinagawa A, Seiki M: Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library — MT-MMPs form a unique membrane-type sublcass in the MMP family. J Biol Chem 270:23013–23020, 1995
Fridman R, Toth M, Pena D, Mobashery S: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 55:2548–2555, 1995
Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6:121–125, 1990
Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327–336, 1991
Ray JM, Stetler-Stevenson WG: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 14:908–917, 1995
Tryggvason K, Hoyhtya M, Pyke C: Type IV collagenases in invasive tumors. Breast Cancer Res Treat 24:209–218, 1993
Cao J, Sato H, Takino T, Seiki M: The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 270:801–805, 1995
Cross M, Dexter TM: Growth factors in development, transformation, and tumorigenesis. Cell 64:271–280, 1991
Dickson RB, Lippman ME: Molecular determinants of growth, angiogenesis and metastases in breast cancer. Semin Oncol 3:286–298, 1992
Blood CH, Zetter BR: Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1032:89–118, 1990
Folkman J: What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82:4–6, 1990
Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchell MA: Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 162:499–510, 1994
Folkman J, Klagsburn M: Angiogenic factors. Science 235:442–447, 1987
Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Eng J Med 324:1–8, 1990
Candle J, Bossy-Weasel E, Radvanyi F, Klagsburn M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095–1104, 1991
Denekamp J, Hobson B: Endothelial-cell proliferation in experimental tumors. Br J Cancer 46:711–720, 1982
Hirst DG, Denekamp J, Hobson B: Proliferation kinetics of endothelial cells and tumor cells in three mouse mammary carcinomas. Cell Tissue Kinet 15:251–261, 1982
Wellstein A, Lippman ME: Fibroblast growth factors and breast cancer. In: Broder S (ed), Molecular Foundations of Oncology. Williams and Wilkins, Baltimore, 1991, p 403
Denekamp J: The current status of targeting tumor vasculature as a means of cancer therapy: an overview. Int J Radiat Biol 60:401–408, 1991
Maione ET, Sharpe RJ: Development of angiogenesis inhibitors for clinical applications. TIPS 11:457–461, 1990
Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M: Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38:969–975, 1995
Hembry RM, Bagga MR, Reynolds JJ, Hamblen DL: Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo-and rheumatoid arthritis. Ann Rheum Dis 54:25–32, 1995
Manicourt DH, Fujimoto N, Obata K, Thonar EJ: Serum levels of collagenase, stromelysin-1, and TIMP-1. Age-and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 37:1774–17783, 1994
Okada Y, Naka K, Kawamura K, Matsumoto T, Nakanishi I, Fujimoto N, Sato H, Seiki M: Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest 72:311–322, 1995
Koolwijk P, Miltenburg AM, van Erck MG, Oudshoorn M, Niedbala MJ, Breedveld FC, van Hinsbergh VW: Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J Rheumatol 22:385–393, 1995
Sepper R, Konttinen YT, Ding Y, Takagi M, Sorsa T: Human neutrophil collagenase (MMP-8), identified in bronchiectasis BAL fluid, correlates with severity of disease. Chest 107:1641–1647, 1995
Shapiro SD: Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med 150:160–164, 1994
Bailey CJ, Hembry RM, Alexander A, Irving MH, Grant ME, Shuttleworth CA: Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intenstine. J. Clin Pathol 47:113–116, 1994
Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, Sato H, Seiki M, Ooshima A, Watanabe A: Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 21:787–795, 1995
Milani S, Herbst H, Schuppan D, Grappone C, Pellegrini G, Pinzani M, Casini A, Calabro A, Ciancio G, Stefanini F: Differential expression of matrix metalloproteinase-1 and-2 genes in normal and fibrotic human liver. Am J Pathol 144:528–537, 1994
Newman KM, Malon AM, Shin RD, Scholes JV, Ramey WG, Tilson MD: Matrix metalloproteinases in abdominal aortic aneurysm: characterization, purification, and their possible sources. Connect Tissue Res 30:265–276, 1994
Irizarry E, Newman KM, Gandhi RH, Nackman GB, Halpern V, Wishner S, Scholes JV, Tilson MD: Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res 54:571–574, 1993
Wysocki AB, Staiano-Coico L, Grinnell F: Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 101:64–68, 1993
Zucker S, Lysik RM, Zarrabi MH, Moll U: Mr 92,000 Type IV collagenase is increased in plasma of patients with colon and breast cancer. Cancer Res 53:140–146, 1993
Brown PD, Bloxidge RE, Stuart NSA, Gatter KC, Carmichael J: Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J Natl Cancer Inst 85:574–578, 1993
Levy TD, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetler-Stevenson WG: Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51:439–444, 1991
Nuovo GJ, MacConnell PB, Simsir A, Valea F, French DL: Correlation of the in situ detection of polymerase chain reactionamplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 55:267–275, 1995
Zucker S, Lysik RM, Zarrabi HM, Moll U, Tickle SP, Stetler-Stevenson W, Baker TS, Docherty AJ: Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment. Ann N Y Acad Sci 732:248–262, 1994
Azzam HS, Arand G, Lippman ME, Thompson EW: Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85:1758–1764, 1993
Zucker S, Lysik RM, Zarrabi MH, Stetler-Stevenson W, Liotta LA, Birkedal-Hansen H, Mann W, Furie M: Type IV collagenase/gelatinase (MMP-2) is not increased in plasma of patients with cancer. Cancer Epidemiol Biomarkers Prev 1:475–479, 1992
Wojtowicz-Praga S, Low J, Dickson R, Ness E, Barter J, McCann P, Hawkins MJ: Phase I study of batimastat (BB-94), a novel matrix metalloproteinase inhibitor in patients with advanced cancer. Invest New Drugs 14:193–202, 1996
Barrett AJ, Starkey PM: The interaction of alpha2-macroglobulin with proteinases. Biochem J 133:703–713, 1973
Sottrup JL, Birkedal HH: Human fibroblast collagenase-alpha-macroglobulin interactions: localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. J Biol Chem 264:393–401, 1989
Grigioni WF, D'Errico A, Fortunato C, Fiorentino M, Mancini AM, Stetler-Stevenson WG, Sobel ME, Liotta LA, Onisto M, Garbisa S: Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol 7:220–225, 1994
Khokha R, Waterhouse P: The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction. J Neurooncol 18:123–127, 1993
Willenbrock F, Murphy G: Structure-function relationships in the tissue inhibitors of metalloproteinases. Am J Respir Crit Care Med 150:165–170, 1994
Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM: Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 59:329–341, 1993
Reynolds JJ, Hembry RM, Meikle MC: Connective tissue degradation in health and periodontal disease and the roles of matrix metalloproteinases and their natural inhibitors. Adv Dent Res 8:312–319, 1994
Clark SD, Kobayashi DK, Welgus HG: Regulation of the expression of tissue inhibitor of metalloproteinases and collagenase by retinoids and glucocorticoids in human fibroblasts. J Clin Invest 80:1280–1288, 1987
Naylor MS, Stamp GW, Davies BD, Balkwill FR: Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 58:50–56, 1994
Polette M, Clavel C, Birembaut P, De Clerck YA: Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathol Res Pract 189:1052–1057, 1993
Takemura M, Azuma C, Kimura T, Kanai T, Saji F, Tanizawa O: Type-IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissues. Int J Gynaecol Obstet 46:303–309, 1994
Mohanam S, Wang SW, Rayford A, Yamamoto M, Sawaya R, Nakajima M, Liotta LA, Nicolson GL, Stetler-Stevenson WG, Rao JS: Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis 13:57–62, 1995
DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52:701–708, 1992
Johnson MD, Kim HR, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160:194–202, 1994
Alvarez OA, Carmichael DF, DeClerck YA: Inhibition of collagenolytic activity and metastasis of tumour cells by a recombinant tissue inhibitor of metalloproteinases. J Natl Cancer Inst 82:589–595, 1990
Khokha R: Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the over-expression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 86:299–304, 1994
Naruo S, Kanayama H, Takigawa H, Kagawa S, Yamashita K, Hayakawa T: Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients. Int J Urol 1:228–231, 1994
Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J: Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 70:506–512, 1994
Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, De Clerck YA: Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 54:5467–5473, 1994
Ray JM, Stetler-Stevenson WG: TIMP-2 expression modulates human melanoma cell adhesion and motility. Ann N Y Acad Sci 732:233–247, 1994
Visscher DW, Hoyhtya M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Fridman R: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59:339–344, 1994
Wilde CG, Hawkins PR, Coleman RT, Levine WB, Delegeane AM, Okamoto PM, Ito LY, Scott RW, Seilhamer JJ: Cloning and characterization of human tissue inhibitor of metalloproteinases-3. DNA Cell Biol 13:711–718, 1994
Kishnani NS, Staskus PW, Yang TT, Masiarz FR, Hawkes SP: Identification and characterization of human tissue inhibitor of metalloproteina-3 and detection of three additional metalloproteinase inhibitor activities in extracellular matrix. Matrix Biol 14:479–488, 1995
Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR: Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269:9352–9360, 1994
Apte SS, Hayashi K, Seldin MF, Mattei MG, Hayashi M, Olsen BR: Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10. Dev Dyn 200:177–197, 1994
Greenwald RA: Treatment of destructive arthritic disorders with MMP inhibitors. Potential role of tetracyclines. Ann N Y Acad Sci 732:181–198, 1994
Burns F, Stack MS, Gray MS, Patterson CA: Inhibition of purified collagenase from alkaline-burned rabbit corneas. Invest Ophtalmol Vis Sci 30:1569–1575, 1989
Karakiulakis G, Missirlis E, Maragoudakis ME: Basement membrane collagen-degrading activity from a malignant tumor is inhibited by anthracycline antibiotics. Biochim Biophys Acta 1035:218–222, 1990
Izquierdo-Martin M, Stein RL: Mechanistic studies on the inhibition of stromelysin by a peptide phosphonamidate. Bioorg Med Chem 1:19–26, 1993
Brown FK, Brown PJ, Bickett DM, Chambers CL, Davies HG, Deaton DN, Drewry D, Foley M, McElroy AB, Gregson M, McGeehan GM, Myers PL, Norton D, Salovich JM, Schoenen FJ, Ward P: Matrix metalloproteinase inhibitors containing a (carboxyalkyl) amino zinc ligand: modification of the P1 and P2' residues. J Med Chem 37:674–688, 1994
Brown PD: Matrix metalloproteinase inhibitors: a new class of anticancer agents. Curr Opin Invest Drugs 2:617–626, 1993
Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087–2091, 1993
Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726–4728, 1994
Chirivi RGS, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD, Giavazzi R: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460–464, 1994
Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD: Inhibition of organ invasion by matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 55:3629–3633, 1995
Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R: Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87:293–298, 1995
Wojtowicz S, Ness E, Dickson R, Low J, Barter J, McCann P, Hawkins M: Pharmacokinetics of batimastat (BB-94), a novel matrix metalloproteinase inhibitor in patients with advanced cancer. Proceedings of ASCO 14:474, 1995
Drummond AH, Beckett P, Bone EA, Brown PD, Davis M, Galloway WA, Taupin P, Wood LM, Davidson AH: BB-2516: An orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models. Proceedings of AACR 36:100, 1995
Beckett RP, Davidson AH, Drummond AH, Huxley P, Whittaker M: Recent advances in matrix metalloproteinase inhibitor research. Drug Discovery Today 1:16–26, 1996
Hornung RL, Pearson JW, Beckwith M, Longo DL: Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor lines: In Vitro versus In Vivo activity. Cancer Res 52:101–107, 1992
Kraft AS, Baker VV, May WS: Bryostatin induces change in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic (HL-60) cells. Oncogene 1:111–118, 1987
Kraft AS: Bryostatin-1: Will the oceans provide a cancer cure? J Natl Cancer Inst 85:1700–1792, 1993
Gopalakrishna R, Barsky SH: Tumor-promoter induced membrane bound protein kinase C regulates hematogenous metastasis. Proc Natl Acad Sci 85:612–616, 1988
Johnson MD, Torri JT, Lippman ME, Dickson RB: Regulation of the invasiveness of the human breast cancer line MCF-7 by agents that act through protein kinase-C. Submitted
Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NS, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F: Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 85:1812–1818, 1993
Prendville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, Pettit GR: A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68:48–424, 1993